ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In this line, the pan-Aurora Kinase inhibitor MK-0457 (VX-680), has been investigated for the treatment of resistant CML patients harboring the BCR-ABL mutation T315I with encouraging results at a dose that did not induce side effects [204] while 44% of the patients had hematological responses [205], and cytogenetic responses were observed in 14% of patients in a phase II study ([206]; NCT00111683).